Does empagliflozin reduce ectopic fat stores and alter myocardial energetics in mice and humans with type 2 diabetes?
Empagliflozin reduces liver fat but does not alter myocardial fat or energetics, rebutting the thrifty substrate hypothesis for the cardiovascular benefits of SGLT2 inhibitors.
EMPA effectively reduced liver fat in mice and humans without changing epicardial, myocardial fat or myocardial energetics, rebutting the thrifty substrate hypothesis for cardiovascular protection of SGLT2 inhibitors. Trial registration NCT, NCT03118336. Registered 18 April 2017, https://clinicaltrials.gov/ct2/show/NCT03118336.
Gaborit et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: